Takeda, Arthritis Foundation launch gout awareness effort

Share this article:
Takeda, Arthritis Foundation launch gout awareness effort
Takeda, Arthritis Foundation launch gout awareness effort

Takeda Pharmaceuticals North America and the Arthritis Foundation launched a gout awareness campaign featuring TV and radio PSAs airing nationally, along with a website, www.goutliving.org.

It's the first-ever high-profile education effort around the disease, said Takeda and the Arthritis Foundation, and it aims to communicate that “ living with the disease “doesn't have to mean missing out on life's special moments.”

The website includes an “attack tracker,” points for discussion with physicians, and a glossary of medical terms.

Takeda's Uloric won FDA approval for chronic management of hyperuricemia in patients with gout last year, becoming the first new gout drug to win approval in four decades.

The PSAs were produced by M Street Creative. PR is being handled by Ketchum.

Coincidentally, the campaign launched a day before Savient's gout drug Krystexxa (pegloticase) won FDA approval as a second-line treatment. Krystexxa has a different mechanism of action than xanthine oxidase inhibitors like Uloric, making it a potentially valuable treatment in patients for whom conventional treatments like the Takeda drug don't work. However, Krystexxa also carries a black box warning of possible severe allergic reaction experienced by a quarter of all patients in clinical trials.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...